trending Market Intelligence /marketintelligence/en/news-insights/trending/n8-kMHVsSqQDHRlSQ6jbFA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Innovent sells US, Canada rights of Avastin biosimilar to Coherus BioSciences

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Innovent sells US, Canada rights of Avastin biosimilar to Coherus BioSciences

Suzhou, China-based Innovent Biologics Inc. agreed to sell the commercial rights to its Avastin biosimilar, IBI305, in the U.S. and Canada to Coherus BioSciences Inc.

A biosimilar is a cheaper version of a biologic therapy. IBI305, for example, will likely be a less expensive substitute for Roche Holding AG's blockbuster drug Avastin — used to treat colorectal, lung, kidney and cervical cancer, among others.

Redwood City, Calif.-based Coherus BioSciences will pay Innovent $45 million up front, plus additional milestone payments when certain goals are achieved, and double-digit percent of royalties on IBI305 sales.

IBI305 has completed a phase 3 study in China, and Innovent has filed an application for marketing approval, which was accepted and granted priority review status by China's National Medical Products Administration.

Coherus BioSciences plans to file a marketing application for IBI305 to the U.S. Food and Drug Administration in late 2020 or early 2021.

Under the deal's terms, Coherus also has a nonexclusive option to license IBI301, Innovent's biosimilar to Rituxan, in the U.S. and Canada with the same financial terms. Rituxan, also sold as MabThera, is another blockbuster Roche medicine used to treat certain blood cancers, including lymphoma and leukemia.